As MR guided focused ultrasound (MRgFUS) treatments evolve to treat oncological diseases, the ability to accurately assess the efficacy of treatment is critical. Although there are several MR metrics proposed for assessing MRgFUS treatments, they have not been rigorously validated against gold standard histopathology treatment assessment. Current validation studies that register MR to histopathology do not comprehensively account for all deformations during histological processing. We present a rigorous MR to histopathology registration pipeline that estimates deformation at every step that can be used to accurately validate the efficacy of oncological MRgFUS treatment.
This abstract and the presentation materials are available to members only; a login is required.